Suivant

Lecture automatique

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

0 Vues • 07/14/23
Partager
Intégrer
administrator
administrator
Les abonnés
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

Montre plus
0 commentaires sort Trier par
Commentaires de Facebook

Suivant

Lecture automatique